Targeting regulatory T cells in cancer and autoimmunity: opposing immune microenvironments, mechanisms of clinical trial failure, and a redesign framework guided by biomarkers

Regulatory T cells (Tregs) are central regulators of immune tolerance. However, therapies targeting Tregs have not yet produced consistent clinical benefits in cancer or autoimmune disease. We propose that one long-underestimated reason is that Tregs are not static drug targets. They are dynamic immune regulatory cells that are continuously shaped by the microenvironment. In the tumor microenvironment (TME), cytokine, metabolic, and epigenetic signals usually promote Treg recruitment, metabolic adaptation, and functional stability. In autoimmune disease, these signals are more often associated with insufficient Treg numbers, unstable phenotypes, or impaired function. Based on this view, we propose a framework of opposing microenvironments. This framework shows that the functional opposition of Tregs in cancer and autoimmunity arises from a fundamental reversal of the microenvironment. We then critically reassess five therapeutic strategies in the two disease settings, including interleukin-2 (IL-2) signaling, co-signaling checkpoints, metabolic regulation, epigenetic reprogramming, and Treg cell therapy. We also summarize representative failed or stalled clinical trials as repeated patterns of failure. Finally, we propose a candidate redesign framework guided by biomarkers. This framework integrates patient stratification, therapeutic direction, dose windows, treatment sequence, efficacy monitoring, and safety monitoring. It may help move Treg therapy from a molecular-targeted approach to a precision immune intervention guided by the microenvironment.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-21
DOI
https://doi.org/10.1186/s12967-026-09230-7
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting regulatory T cells in cancer and autoimmunity: opposing immune microenvironments, mechanisms of clinical trial failure, and a redesign framework guided by biomarkers

Yuehong Hu, 姜寒雪, Hongliang Rui, Baoli Liu et al.
Journal of Translational Medicine
T-cell and B-cell Immunology
article

Targeting regulatory T cells in cancer and autoimmunity: opposing immune microenvironments, mechanisms of clinical trial failure, and a redesign framework guided by biomarkers

Yuehong Hu, 姜寒雪, Hongliang Rui, Baoli Liu, Wenbin Liu, Haoran Dai, Qihan Zhao, Xiaoyu Cui, Yadi Wu
article en

Abstract

Regulatory T cells (Tregs) are central regulators of immune tolerance. However, therapies targeting Tregs have not yet produced consistent clinical benefits in cancer or autoimmune disease. We propose that one long-underestimated reason is that Tregs are not static drug targets. They are dynamic immune regulatory cells that are continuously shaped by the microenvironment. In the tumor microenvironment (TME), cytokine, metabolic, and epigenetic signals usually promote Treg recruitment, metabolic adaptation, and functional stability. In autoimmune disease, these signals are more often associated with insufficient Treg numbers, unstable phenotypes, or impaired function. Based on this view, we propose a framework of opposing microenvironments. This framework shows that the functional opposition of Tregs in cancer and autoimmunity arises from a fundamental reversal of the microenvironment. We then critically reassess five therapeutic strategies in the two disease settings, including interleukin-2 (IL-2) signaling, co-signaling checkpoints, metabolic regulation, epigenetic reprogramming, and Treg cell therapy. We also summarize representative failed or stalled clinical trials as repeated patterns of failure. Finally, we propose a candidate redesign framework guided by biomarkers. This framework integrates patient stratification, therapeutic direction, dose windows, treatment sequence, efficacy monitoring, and safety monitoring. It may help move Treg therapy from a molecular-targeted approach to a precision immune intervention guided by the microenvironment.

Journal of Translational Medicine
Capital Medical University (CN), Beijing Hospital of Traditional Chinese Medicine (CN)
T-cell and B-cell Immunology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon